ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important November 17 Deadline in Securities Class Action - CYTK

Core Points - Rosen Law Firm is encouraging investors of Cytokinetics, Inc. to secure counsel before the November 17, 2025 lead plaintiff deadline for a securities class action lawsuit [2][4] - Investors who purchased Cytokinetics common stock between December 27, 2023, and May 6, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3] - The lawsuit alleges that Cytokinetics made false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten, which led to investor damages when the truth was revealed [6] Company Background - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [5] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5] Legal Details - The lawsuit claims that Cytokinetics misrepresented the expected FDA approval timeline for aficamten and failed to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS) [6]